Navicixizumab Biosimilar（Anti-DLL4 Reference Antibody） Datasheet DC Chemicals
Description Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel.html" class="link-product" target="_blank"> Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer.
Cat.No A882
Name Navicixizumab Biosimilar（Anti-DLL4 Reference Antibody）

Chemical Properties

CAS 1638338-43-8
Synonyms Navicixizumab;OMP 305B83;Research Grade Navicixizumab (DHJ65303);Research Grade Navicixizumab (DHJ65303);Research Grade Navicixizumab (DHJ65303);Research Grade Navicixizumab (DHJ65303)
pH value Corresponds to reference standard: PASS
Non-reduced CE-SDS >95%
SEC-HPLC >95%
Isoelectric Point Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality Corresponds to reference standard: PASS
Peptide mapping Corresponds to reference standard: PASS
N-terminal sequence Corresponds to reference standard: PASS

References

Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com